Related Experiment Video
Updated: Dec 13, 2025
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
435
Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.
Omar Castaneda Puglianini1, Nikolaos Papadantonakis2
1Virginia Commonwealth University, Massey Cancer Center, Cellular Immunotherapies and Transplant Program, Richmond, Virginia, USA.
Therapeutic Advances in Hematology
|August 1, 2020
Summary
Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is difficult to treat. This review explores emerging molecularly targeted therapies, including venetoclax, for managing this rare leukemia.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) represents a rare and aggressive subtype of leukemia.
- ETP-ALL is associated with inherent chemo-resistance, complicating treatment strategies.
- Limited data exists on the optimal management protocols for ETP-ALL patients.
Purpose of the Study:
- To review the current literature on the management of ETP-ALL.
- To highlight emerging therapeutic strategies for ETP-ALL.
- To focus on the potential role of molecularly targeted agents, specifically venetoclax.
Main Methods:
- Comprehensive literature search of studies related to ETP-ALL management.
- Analysis of recent clinical data and research findings.
- Review of molecularly targeted approaches in leukemia therapy.
Main Results:
- ETP-ALL exhibits significant chemo-resistance, necessitating novel treatment paradigms.
- Molecularly targeted therapies show promise in overcoming resistance mechanisms.
- Venetoclax is emerging as a potential therapeutic option for ETP-ALL.
Conclusions:
- Optimal management of ETP-ALL requires exploring novel therapeutic avenues beyond conventional chemotherapy.
- Targeted therapies, such as venetoclax, offer a promising direction for improving outcomes in ETP-ALL.
- Further research is crucial to establish the efficacy and safety of venetoclax in ETP-ALL treatment.
Related Concept Videos
01:23Cells of the Adaptive Immune Response
8.2K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.2K
01:15Differentiation of Common Myeloid Progenitor Cells
3.8K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.8K
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
01:21Lineage Commitment
3.9K
Commitment is the process whereby stem cells:
3.9K